Marvel Biosciences Corp. (MRVL.V) Research

Based in Calgary, Canada, Marvel Biosciences Corp. is a biotechnology firm dedicated to pre-clinical pharmaceutical development. The company focuses on identifying and advancing synthetic derivatives of existing medications, specifically those designed to inhibit the A2a adenosine receptor. Among its key assets are Nourianz (also known as Istradefylline or KW-6002) and MB-204, both of which function as adenosine A2A receptor antagonists. Its therapeutic pipeline addresses a range of conditions, including neurological disorders like Alzheimer's disease, depression, and anxiety, as well as non-neurological illnesses such as various cancers and non-alcoholic steatohepatitis (NASH).

Market snapshot

Symbol
MRVL.V
Price
$0.20
Day change
+8.33%
Market cap
$12.3M
P/E ratio
-7.30x
52-week range
0.115-0.4
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BetterLife Pharma Inc. (BETR.CN)
  • BioVaxys Technology Corp. (BIOV.CN)
  • Britannia Life Sciences Inc. (BLAB.CN)
  • Comprehensive Healthcare Systems, Inc. (CHS.V)
  • Delivra Health Brands Inc. (DHB.V)
  • Glow Lifetech Corp. (GLOW.CN)
  • Pharmala Biotech Holdings Inc. (MDMA.CN)
  • Medicure Inc. (MPH.V)

Open Marvel Biosciences Corp. (MRVL.V) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.